Cargando…

Cost-Effectiveness of Blood-Based Brain Biomarkers for Screening Adults with Mild Traumatic Brain Injury in the French Health Care Setting

Two blood-based brain biomarker tests such as the combination of glial fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 (GFAP+UCH-L1) or S100B have potential to reduce the need for head computed tomography (CT) scanning in patients with mild traumatic brain injury (mTBI). We assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmer, Louise, McDade, Cheryl, Beyhaghi, Hadi, Purser, Molly, Textoris, Julien, Krause, Alexander, Blanc, Esther, Pavlov, Vladislav, Earnshaw, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061334/
https://www.ncbi.nlm.nih.gov/pubmed/36267001
http://dx.doi.org/10.1089/neu.2022.0270
_version_ 1785017269134295040
author Zimmer, Louise
McDade, Cheryl
Beyhaghi, Hadi
Purser, Molly
Textoris, Julien
Krause, Alexander
Blanc, Esther
Pavlov, Vladislav
Earnshaw, Stephanie
author_facet Zimmer, Louise
McDade, Cheryl
Beyhaghi, Hadi
Purser, Molly
Textoris, Julien
Krause, Alexander
Blanc, Esther
Pavlov, Vladislav
Earnshaw, Stephanie
author_sort Zimmer, Louise
collection PubMed
description Two blood-based brain biomarker tests such as the combination of glial fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 (GFAP+UCH-L1) or S100B have potential to reduce the need for head computed tomography (CT) scanning in patients with mild traumatic brain injury (mTBI). We assessed the clinical and economic impact of using GFAP+UCH-L1 versus CT scan and GFAP+UCH-L1 versus S100B to screen adults with suspected mTBI presenting to an emergency department (ED). A decision model was developed to estimate costs and health outcomes of GFAP+UCH-L1, CT scan, and S100B associated with these screening protocols. Model parameters were extracted from peer-reviewed articles, clinical guidelines, and expert opinion. Analysis was performed from a French health care system perspective (costs in 2020 euros). In the model, patients with a positive biomarker receive a CT scan to confirm the presence of intracranial lesions (ICLs). Depending on clinical state and biomarker and CT results, patients were discharged immediately, kept for observation in the ED, admitted for in-hospital stay and observation, or admitted for surgical management. Incorrect test results may lead to delayed treatment and poor outcomes or overtreatment. GFAP+UCH-L1 use was associated with an overall decrease in CT scans when compared with CT screening or S100B use (325.42 and 46.43 CTs per 1000 patients, respectively). The use of GFAP+UCH-L1 resulted in modest cost savings when compared with CT scanning and with S100B. In all cases, use of GFAP+UCH-L1 marginally improved quality-adjusted life-years (QALYs) and outcomes. Thus, screening with GFAP+UCH-L1 reduced the need for CT scans when compared with systematic CT scan screening or use of S100B while maintaining similar costs and health outcomes.
format Online
Article
Text
id pubmed-10061334
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-100613342023-03-31 Cost-Effectiveness of Blood-Based Brain Biomarkers for Screening Adults with Mild Traumatic Brain Injury in the French Health Care Setting Zimmer, Louise McDade, Cheryl Beyhaghi, Hadi Purser, Molly Textoris, Julien Krause, Alexander Blanc, Esther Pavlov, Vladislav Earnshaw, Stephanie J Neurotrauma Original Articles Two blood-based brain biomarker tests such as the combination of glial fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 (GFAP+UCH-L1) or S100B have potential to reduce the need for head computed tomography (CT) scanning in patients with mild traumatic brain injury (mTBI). We assessed the clinical and economic impact of using GFAP+UCH-L1 versus CT scan and GFAP+UCH-L1 versus S100B to screen adults with suspected mTBI presenting to an emergency department (ED). A decision model was developed to estimate costs and health outcomes of GFAP+UCH-L1, CT scan, and S100B associated with these screening protocols. Model parameters were extracted from peer-reviewed articles, clinical guidelines, and expert opinion. Analysis was performed from a French health care system perspective (costs in 2020 euros). In the model, patients with a positive biomarker receive a CT scan to confirm the presence of intracranial lesions (ICLs). Depending on clinical state and biomarker and CT results, patients were discharged immediately, kept for observation in the ED, admitted for in-hospital stay and observation, or admitted for surgical management. Incorrect test results may lead to delayed treatment and poor outcomes or overtreatment. GFAP+UCH-L1 use was associated with an overall decrease in CT scans when compared with CT screening or S100B use (325.42 and 46.43 CTs per 1000 patients, respectively). The use of GFAP+UCH-L1 resulted in modest cost savings when compared with CT scanning and with S100B. In all cases, use of GFAP+UCH-L1 marginally improved quality-adjusted life-years (QALYs) and outcomes. Thus, screening with GFAP+UCH-L1 reduced the need for CT scans when compared with systematic CT scan screening or use of S100B while maintaining similar costs and health outcomes. Mary Ann Liebert, Inc., publishers 2023-04-01 2023-03-28 /pmc/articles/PMC10061334/ /pubmed/36267001 http://dx.doi.org/10.1089/neu.2022.0270 Text en © Louise Zimmer et al., 2023; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by/4.0/This Open Access article is distributed under the terms of the Creative Commons License (CC-BY) (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Original Articles
Zimmer, Louise
McDade, Cheryl
Beyhaghi, Hadi
Purser, Molly
Textoris, Julien
Krause, Alexander
Blanc, Esther
Pavlov, Vladislav
Earnshaw, Stephanie
Cost-Effectiveness of Blood-Based Brain Biomarkers for Screening Adults with Mild Traumatic Brain Injury in the French Health Care Setting
title Cost-Effectiveness of Blood-Based Brain Biomarkers for Screening Adults with Mild Traumatic Brain Injury in the French Health Care Setting
title_full Cost-Effectiveness of Blood-Based Brain Biomarkers for Screening Adults with Mild Traumatic Brain Injury in the French Health Care Setting
title_fullStr Cost-Effectiveness of Blood-Based Brain Biomarkers for Screening Adults with Mild Traumatic Brain Injury in the French Health Care Setting
title_full_unstemmed Cost-Effectiveness of Blood-Based Brain Biomarkers for Screening Adults with Mild Traumatic Brain Injury in the French Health Care Setting
title_short Cost-Effectiveness of Blood-Based Brain Biomarkers for Screening Adults with Mild Traumatic Brain Injury in the French Health Care Setting
title_sort cost-effectiveness of blood-based brain biomarkers for screening adults with mild traumatic brain injury in the french health care setting
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061334/
https://www.ncbi.nlm.nih.gov/pubmed/36267001
http://dx.doi.org/10.1089/neu.2022.0270
work_keys_str_mv AT zimmerlouise costeffectivenessofbloodbasedbrainbiomarkersforscreeningadultswithmildtraumaticbraininjuryinthefrenchhealthcaresetting
AT mcdadecheryl costeffectivenessofbloodbasedbrainbiomarkersforscreeningadultswithmildtraumaticbraininjuryinthefrenchhealthcaresetting
AT beyhaghihadi costeffectivenessofbloodbasedbrainbiomarkersforscreeningadultswithmildtraumaticbraininjuryinthefrenchhealthcaresetting
AT pursermolly costeffectivenessofbloodbasedbrainbiomarkersforscreeningadultswithmildtraumaticbraininjuryinthefrenchhealthcaresetting
AT textorisjulien costeffectivenessofbloodbasedbrainbiomarkersforscreeningadultswithmildtraumaticbraininjuryinthefrenchhealthcaresetting
AT krausealexander costeffectivenessofbloodbasedbrainbiomarkersforscreeningadultswithmildtraumaticbraininjuryinthefrenchhealthcaresetting
AT blancesther costeffectivenessofbloodbasedbrainbiomarkersforscreeningadultswithmildtraumaticbraininjuryinthefrenchhealthcaresetting
AT pavlovvladislav costeffectivenessofbloodbasedbrainbiomarkersforscreeningadultswithmildtraumaticbraininjuryinthefrenchhealthcaresetting
AT earnshawstephanie costeffectivenessofbloodbasedbrainbiomarkersforscreeningadultswithmildtraumaticbraininjuryinthefrenchhealthcaresetting